| Literature DB >> 25689642 |
Kristina Mickevičienė1, Rūta Baranauskaitė2, Kristina Kantminienė3, Maryna Stasevych4, Olena Komarovska-Porokhnyavets5, Volodymyr Novikov4.
Abstract
3-[(2-Hydroxyphenyl)amino]butanoic and 3-[(2-hydroxy-5-methyl(chloro)phenyl)amino]butanoic acids were converted to a series of derivatives containing hydrazide, pyrrole and chloroquinoxaline moieties. The corresponding benzo[b]phenoxazine derivatives were synthesized by the reaction of the obtained compounds with 2,3-dichloro-1,4-naphthoquinone. Five of the synthesized compounds exhibited good antimicrobial activity against Staphylococcus aureus and Mycobacterium luteum, whereas three compounds showed significant antifungal activity against Candida tenuis and Aspergillus niger.Entities:
Mesh:
Substances:
Year: 2015 PMID: 25689642 PMCID: PMC6272739 DOI: 10.3390/molecules20023170
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Scheme 1Transformation reactions of 3-[(2-hydroxyphenyl)amino]-butanoic acids 2a–c and synthesis of ethyl-3-[(2-hydroxy-5-substitutedphenyl)amino]but-2-enoates 8a–c.
Scheme 2Synthesis of benzo[b]phenoxazine derivatives.
Antimicrobial activity of the synthesized compounds determined by diffusion method (only compounds that gave positive results at least in one case are included in the table).
| Compound | Conc. (%) | Inhibition Diameter of Microorganism Growth (mm) | ||||
|---|---|---|---|---|---|---|
| Bacteria | Fungi | |||||
| 0.5 | 0 | 0 | 13.0 (b/s) | 0 | 12.0 (f/s) | |
| 0.1 | 0 | 0 | 0 | 0 | 0 | |
| 0.5 | 0 | 0 | 16.0 (b/s) | 0 | 10.0 (f/s) | |
| 0.1 | 0 | 0 | 0 | 0 | 0 | |
| 0.5 | 0 | 22.4 | 15.0 | 12.0 (f/s) | 0 | |
| 0.1 | 0 | 15.4 | 0 | 0 | 0 | |
| 0.5 | 0 | 24.4 | 19.4 | 0 | 0 | |
| 0.1 | 0 | 14.4 | 10.0 (b/s) | 0 | 0 | |
| 0.5 | 8.0 | 23.4 | 23.0 | 20.0 (f/s) | 0 | |
| 0.1 | 0 | 14.0 | 0 | 15.0 (f/s) | 0 | |
| 0.5 | 0 | 0 | 7.0 (b/s) | 0 | 0 | |
| 0.1 | 0 | 0 | 0 | 0 | 0 | |
| 0.5 | 0 | 0 | 11.4 | 0 | 0 | |
| 0.1 | 0 | 0 | 6.0 | 0 | 0 | |
| 0.5 | 0 | 23.7 | 20.7 | 0 | 0 | |
| 0.1 | 0 | 18.7 | 10.0 (b/s) | 0 | 0 | |
| 0.5 | 0 | 0 | 0 | 10.0 (f/s) | 0 | |
| 0.1 | 0 | 0 | 0 | 0 | 0 | |
| 0.5 | 8.0 (b/s) | 0 | 0 | 0 | 0 | |
| 0.1 | 0 | 0 | 0 | 0 | 0 | |
| 0.5 | 0 | 8.0 | 0 | 0 | 0 | |
| 0.1 | 0 | 7.0 (b/s) | 0 | 0 | 0 | |
| 0.5 | 0 | 7.7 | 0 | 0 | 0 | |
| 0.1 | 0 | 0 | 0 | 0 | 0 | |
| 0.5 | 0 | 24.0 | 15.4 | 0 | 0 | |
| 0.1 | 0 | 13.4 | 6.0 | 0 | 0 | |
| 0.5 | 0 | 11.7 | 13.0 | 0 | 24.4 | |
| 0.1 | 0 | 7.7 | 10.0 | 0 | 20.0 | |
| 0.5 | 0 | 0 | 11.0 | 0 | 0 | |
| 0.1 | 0 | 0 | 0 | 0 | 0 | |
| 0.1 | 14.0 | 15.0 | 18.0 | 19.0 | 20.0 | |
Notes: * Vancomycin was used as a control in the tests of antibacterial acitvity of the synthesized compounds, and nystatin was used in the tests of antifungal activity; b/s—bacteriostatic activity; f/s—fungistatic activity.
Bactericidal activity of the synthesized compounds determined by serial dilution method (only compounds that gave positive results at least in one case are included in the table).
| Comp. | |||
|---|---|---|---|
| MIC (µg/mL) | |||
| + | + | 500.0 | |
| + | + | 500.0 | |
| + | + | 500.0 | |
| + | 500.0 | 250.0 | |
| + | 250.0 | 500.0 | |
| + | 500.0 | 250.0 | |
| + | 62.5 | 62.5 | |
| + | 31.2 | 62.5 | |
| 500.0 | 31.2 | 62.5 | |
| + | + | 62.5 | |
| + | 31.2 | 31.2 | |
| 500.0 | + | + | |
| + | 31.2 | 62.5 | |
| + | + | 31.2 | |
| + | + | 15.6 | |
| 31.2 | 3.9 | 7.8 | |
Notes: +: Growth of microorganisms; * Vancomycin was used as a control.
Fungicidal activity of the synthesized compounds determined by serial dilution method (only compounds that gave positive results at least in one case are included in the table).
| Compound | ||
|---|---|---|
| MIC (µg/mL) | ||
| 125.0 | + | |
| + | 125.0 | |
| 15.6 | 250.0 | |
| 31.2 | + | |
| 31.2 | 125.0 | |
| + | 250.0 | |
| 250.0 | 62.5 | |
| 500.0 | + | |
| + | 125.0 | |
| + | 125.0 | |
| + | 62.5 | |
| + | 3.9 | |
| 7.8 | 15.6 | |
Notes: +: Growth of microorganisms; * Nystatin was used as a control.